Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PTGFR | P43088 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549739 | 0.86 | TACR1 (0.35) | TACR1MEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL19000495 | 0.82 | ALOX5AP (0.33) | MAPTHTTSMN1; SMN2 | |
| SCHEMBL14126456 | 0.78 | NQO2 (0.35) | MAPTMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL7537935 | 0.76 | MAOB (0.41) | MAPTMEN1LMNAKMT2A | |
| SCHEMBL17159412 | 0.76 | LMNA (0.37) | TACR1MEN1LMNAHTTKMT2A | |
| SCHEMBL5561672 | 0.74 | IDO1 (0.41) | TACR1LMNAHTTSMN1; SMN2 | |
| SCHEMBL147397 | 0.74 | LMNA (0.36) | PTGFRLMNAHTTSMN1; SMN2NPSR1 | |
| SCHEMBL1853659 | 0.74 | AKR1B1 (0.34) | TACR1HTTSMN1; SMN2 | |
| SCHEMBL5054243 | 0.74 | ALDH1A1 (0.33) | MEN1LMNAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL5553479 | 0.74 | ALDH1A1 (0.41) | MAPTHTTKMT2ASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-7244861-B2 | Benzene compound and salt thereof | EISAI CO., LTD. (JP) | 2007-07-17 | — | — | US | disclosed |
| US-20040138271-A1 | Benzene compound and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1375472-A1 | BENZENE COMPOUND AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138271-A1 | Benzene compound and salt thereof | INSR, SLC5A1, IRS1 | TACR1 859/4885MAPT 4358/4885PTGFR 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.